Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).

Mario Campone,Aditya Bardia,Gary A. Ulaner,Sarat Chandarlapaty,Alice Gosselin,Séverine Doroumian,Vasiliki Pelekanou,Marina Celanovic,Hannah M. Linden

Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).

2020

Mario Campone
Aditya Bardia
Gary A. Ulaner
Sarat Chandarlapaty
Alice Gosselin
Séverine Doroumian
Vasiliki Pelekanou
Marina Celanovic
Hannah M. Linden

1070Background: SERDs competitively antagonize and degrade the ER and can block signaling in ER-dependent tumors resistant to standard endocrine therapy (ET). This study (NCT03284957) investigates ...

Keywords:

Human Epidermal Growth Factor Receptor 2
Metastatic breast cancer
Pathology
Estrogen receptor
phase i ii
Cancer research
Medicine
endocrine therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations